Enterobacteriaceae Infections Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
- Transparency Market Research
Enterobacteriaceae infections are caused by Enterobacter species, pathogens responsible for causing severe infections including bacteremia, urinary tract infections, lower respiratory tract infections, skin and soft tissue infections, and intra-abdominal infections. Signs and symptoms of Enterobacteriaceae infections include fever, hypotension and shock, septic shock, lower respiratory tract infections, etc. These infections need to be treated immediately with the usage of antimicrobial drugs. Major antibiotics involved to manage these infections include beta-lactams, carbapenems, amino-glycosides, fluoroquinolones, and TMP-SMZ. The choice of appropriate antibiotics is very important since many enterobacter species are resistant to antibiotics. A thorough understanding of anti-microbial resistance is important before prescribing the medication, since the genes that code resistance are mobile and can move between plasmids and also between different species and strains which are not resistance currently, but can become resistant in the future. The market drug resistance mediators include broad spectrum beta-lactamases, carbapenemases, extended-spectrum beta lactamases (ESBL), AmpC beta lactamases, modification of enzymes, alterated enzymes, decreased permeability, etc.
Rising prevalence of Enterobacteriaceae infectious diseases, increasing rate of new infections, and the continuous mutations in the microorganisms leading to new strains, are the driving factors driving the infectious diseases treatment market. Furthermore, increasing modes of transmission of the infectious disease and a lack of cleanliness in developing regions has fueled the infectious diseases market. However, asymptomatic conditions of infectious diseases, a lack of treatment for certain diseases, false positive results with certain tests are likely to hamper the expansion of tye infectious diseases testing market. The only restraining factor of the market is the rapid resistance to drugs currently available for enterobacter infections.
The global Enterobacteriaceae infections treatment market can be segmented based on antimicrobial drugs, distribution channel, and geography. Based on antimicrobial drug class, the market is segregated into beta-lactams, carbapenems, fluoroquinolones, aminoglycosides, and TMP-SMZ (Trimethoprim/Sulfamethoxazole). Beta-lactam drugs include penicillins, cephalosporins etc. Amongst these, cephalosporin drug class have good activity, while the activity of carbapenems is excellent. Tigecycline is the most recent drug class utilized in the treatment of Enterobacteriaceae infections. Recently, FDA approved meropenem/vaborbactam for complicated urinary tract infections resulting from carbapenem-resistant Enterobacteriaceae infections. In terms of distribution channel, the global Enterobacteriaceae infections treatment market can be segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital and retail pharmacies segments are witnessing rapid expansion due to the requirement of extended hospitalization due to these infections and also post-hospitalization course of treatment needs to be completed.
In terms of geography, the global Enterobacteriaceae infection treatment market is segregated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is expected to expand during the forecast period, followed by Europe, due to the rise in demand for advanced treatment, rise in healthcare expenditure, and increased diagnosis rate. The market in Asia Pacific is likely to expand at a rapid rate due to the developing healthcare infrastructure, increased government expenditure, and higher number of patients in developing economies in the region.
Key market players operating in the Enterobacteriaceae infections treatment market include Genentech, Inc., Nanotherapeutics, Inc., Novartis AG, Pfizer Inc., Nymox Pharmaceutical Corporation, Sequoia Sciences, Inc., TheraCarb Inc., Phico Therapeutics Ltd., and Cantab Biopharmaceuticals Limited.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Have query on this report?Make an Enquiry
The team was the biggest help to us. Not only were we provided with customized solutions but also we were guided through the most complicated situations. The information was on-point yet comprehensive. The experience was absolutely satisfying and helped us turn many challenges into opportunities.
Ours is a startup with a unique set of challenges and we were therefore hesitant but the team totally put us at ease with their knowledge and expertise. Our business and its challenges were understood perfectly and help was extended accordingly. The tailor made approach really helped us gain the most informative insights.
The report repository is absolutely impressive –updated and exhaustive in terms of markets covered and information provides. Besides, with the support extended to us by the team, we could reduce costs as well as move to sustainable growth. This really helped us tap into new opportunities. Happy to have gone ahead with ResearchMos.us.
We have had a long term engagement with ResearchMoz.us and never have we felt that the work done and help extended were below flawless. The report repository is one of the best one can hope to tap into. Recently, our partner businesses opted for consultancy services and they are all thrilled with the outcome.
Insights from reports helped us improve our profit margins significantly. Most of the knowledge we needed on the market were provided to us on a granular basis. From trends, and drivers to competitive analysis, the information was not just crisp but also insightful. That helped us chart a robust growth strategy and as of now we are happy to state that we are reaping big benefits.
More from Pharmaceutical
PharmaceuticalChinese Markets for Mental Illness Drugs
PharmaceuticalChinese Markets for Anti-Dermatomycosis Skin Drugs
PharmaceuticalChinese Markets for Incretion Drugs
PharmaceuticalChinese Markets for Hypertension Drugs
Pharmaceuticals and HealthcareGlobal Bionic Ears Market Professional Survey Report 2017
Pharmaceuticals and HealthcareNeuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Pharmaceuticals and HealthcareHepatitis Drug Development Pipeline Review, 2017